NCT00537407 - A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Chronic Hepatitis C

Interventions

DRUG

Debio 025

Debio 025 supplied as a 100 mg/mL oral solution

DRUG

Peg-IFNα2a

Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes

DRUG

Ribavirin

Ribavirin supplied as 200 mg tablets

Trial Locations (7)

The Johns Hopkins University School of Medicine, Baltimore

Metropolitan Research, Fairfax

University of Florida, Gainesville

University of Miami Center for Liver Diseases, Miami

Methodist Transplant Physicians, Dallas

Scripps Clinic Liver Disease Research Center, La Jolla

Virginia Mason Medical Center, Seattle